Patents by Inventor Decio L. Eizirik

Decio L. Eizirik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-DPP6 CHIMERIC ANTIGEN RECEPTOR BEARING REGULATORY T CELLS
    Publication number: 20230381228
    Abstract: The present disclosure relates generally to regulatory T cells (Tregs) engineered to express a dipeptidyl aminopeptidase-like protein 6 (DPP6)-reactive chimeric antigen receptor (CAR). The engineered Tregs are suitable for use in immunotherapy regimens for autoimmune, inflammatory and degenerative diseases. In particular, the anti-DPP6 CAR expressing Tregs are suitable for treating or preventing autoimmune diseases of the pancreas or central nervous system.
    Type: Application
    Filed: October 29, 2021
    Publication date: November 30, 2023
    Applicants: The Regents of the University of California, Université Libre de Bruxelles, Vrije Universiteit Brussel
    Inventors: Qizhi TANG, Jeffrey A. BLUESTONE, Emilie RONIN, Decio L. EIZIRIK, Nick M. DEVOOGDT
  • Molecules specifically binding pancreatic beta cells biomarkers
    Patent number: 8981053
    Abstract: The present invention provides a synthetic peptide molecule that specifically binds an FXYD2-gamma isoform of pancreatic beta cells, said synthetic peptide molecule has 25 amino acids.
    Type: Grant
    Filed: June 22, 2012
    Date of Patent: March 17, 2015
    Assignees: Universite de Mons, Université Libre de Bruxelles, Eurogentec SA
    Inventors: Robert Muller, Decio L. Eizirik, Corine Sermeus, Sophie Laurent, Carmen Burtea, Marie-Claire Beckers, Daisy Flamez
  • MOLECULES SPECIFICALLY BINDING PANCREATIC BETA CELLS BIOMARKERS
    Publication number: 20140105823
    Abstract: The present invention provides a synthetic peptide molecule that specifically binds an FXYD2-gamma isoform of pancreatic beta cells, said synthetic peptide molecule has 25 amino acids.
    Type: Application
    Filed: June 22, 2012
    Publication date: April 17, 2014
    Applicants: UNIVERSITÉ DE MONS, EUROGENTEC SA, UNIVERSITÉ LIBRE DE BRUXELLES
    Inventors: Robert Muller, Decio L. Eizirik, Corine Sermeus, Sophie Laurent, Carmen Burtea, Marie-Claire Beckers, Daisy Flamez
  • Plasma membrane biomarkers preferentially expressed in pancreatic beta cells useful in imaging or targeting beta cells
    Patent number: 8425878
    Abstract: The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. It was selected by a Systems Biology approach on Massively Parallel Signal Sequencing datasets obtained in human islets and Affymetrix microarray datasets on human islets, purified rat primary beta and non beta cells and insulinoma cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1 D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration).
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: April 23, 2013
    Assignee: Universite Libre de Bruxelles
    Inventors: Decio L. Eizirik, Daisy Flamez, Isabelle Salmon, Alix Berton, Isabelle Roland, Daniel Marechal, Marie-Claire Beckers, Leroy Hood, Nathan Goodman, Burak Kutlu
  • NEW PLASMA MEMBRANE BIOMARKERS PREFERENTIALLY EXPRESSED IN PANCREATIC BETA CELLS USEFUL IN IMAGING OR TARGETING BETA CELLS
    Publication number: 20100322850
    Abstract: The present invention is directed to the identification of a biomarker specifically located in the plasma membrane of pancreatic beta cells. It was selected by a Systems Biology approach on Massively Parallel Signal Sequencing datasets obtained in human islets and Affymetrix microarray datasets on human islets, purified rat primary beta and non beta cells and insulinoma cells. Based on a set of specific features the biomarker is a unique candidate for imaging and targeting strategies to study the pancreatic beta cell mass in health and disease (T1 D, T2D, pancreatic cancers, obesity, islet transplantation, beta cell regeneration).
    Type: Application
    Filed: February 13, 2009
    Publication date: December 23, 2010
    Inventors: Decio L. Eizirik, Daisy Flamez, Isabelle Salmon, Alix Berton, Isabelle Roland, Daniel Marechal, Marie-Claire Beckers, Leroy Hood, Nathan Goodman, Burak Kutlu